Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Progestogen

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    695 result(s) found for: Progestogen. Displaying page 1 of 35.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2020-003688-25 Sponsor Protocol Number: INS1007-301 Start Date*: 2021-04-08
    Sponsor Name:Insmed Incorporated
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibros...
    Medical condition: Non-Cystic Fibrosis Bronchiectasis
    Disease: Version SOC Term Classification Code Term Level
    23.0 10038738 - Respiratory, thoracic and mediastinal disorders 10083611 Non-cystic fibrosis bronchiectasis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PT (Completed) DK (Completed) NL (Completed) IE (Completed) HU (Completed) GR (Completed) PL (Completed) BG (Completed) LT (Prematurely Ended) SK (Completed) AT (Completed) FR (Completed) EE (Prematurely Ended) BE (Completed) IT (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-006044-14 Sponsor Protocol Number: EB05-04-2020 Start Date*: 2021-10-25
    Sponsor Name:Edesa Biotech Research Inc.
    Full Title: A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of EB05 + SOC vs. placebo + SOC in adult hospitalized patients with COVID19
    Medical condition: SARS-CoV-2 Positive Pneumonia - level 3-7 in the nine-point COVID-19 severity scale:
    Disease: Version SOC Term Classification Code Term Level
    23.1 10021881 - Infections and infestations 10084380 COVID-19 pneumonia PT
    23.1 10021881 - Infections and infestations 10084383 Novel COVID-19-infected pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003921-27 Sponsor Protocol Number: DORAGEN Start Date*: 2019-06-25
    Sponsor Name:Lluita contra la SIDA Foundation
    Full Title: Doravirine concentrations and antiviral activity in genital fluids in HIV-1 infected individuals.
    Medical condition: HIV infected individuals
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-001259-29 Sponsor Protocol Number: UoL001306 Start Date*: 2019-03-12
    Sponsor Name:University of LIverpool
    Full Title: A PHASE 1B/2A STUDY TO ASSESS THE TOLERABILITY AND ADVERSE EFFECT PROFILE OF CYSTEAMINE (CYSTAGON) IN ADULTS AND CHILDREN WITH HOMOZYGOUS ΔF508 CYSTIC FIBROSIS, IN PATIENTS TAKING EPIGALLOCATECHIN-...
    Medical condition: DeltaF508 Homozygous Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001036-25 Sponsor Protocol Number: UNI91103-201 Start Date*: 2021-06-01
    Sponsor Name:UNION therapeutics A/S
    Full Title: A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF UNI91103 INTRANASAL ADMINISTRATION IN ADULTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC COVID-19
    Medical condition: Covid-19
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-001528-16 Sponsor Protocol Number: INS1009-202 Start Date*: 2022-05-30
    Sponsor Name:Insmed Incorporated
    Full Title: A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to valuate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in participants with Pu...
    Medical condition: Participants with Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-003050-32 Sponsor Protocol Number: FAB122-CT-2201 Start Date*: 2023-02-21
    Sponsor Name:Ferrer Internacional S.A.
    Full Title: A multicenter, open-label extension study to investigate the long-term safety of FAB122 in patients with Amyotrophic Lateral Sclerosis
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) PL (Prematurely Ended) DE (Completed) SE (Completed) BE (Completed) ES (Completed) PT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-022383-12 Sponsor Protocol Number: CCX114157 Start Date*: 2011-02-16
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A 52 week Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Maintenance of Remission in Subjects with Crohn’s Disease
    Medical condition: Subjects with Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    16.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) DE (Completed) NO (Prematurely Ended) BE (Completed) SE (Prematurely Ended) GB (Prematurely Ended) DK (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) GR (Prematurely Ended) AT (Completed) ES (Prematurely Ended) PL (Prematurely Ended) PT (Prematurely Ended) EE (Prematurely Ended) IT (Completed) SK (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003351-65 Sponsor Protocol Number: RDD110 Start Date*: 2016-03-16
    Sponsor Name:RDD Pharma Ltd.
    Full Title: The Effect of Intra-anal Nifedipine, Used As Add-on to Conservative Therapy, on Pain in Patients with Anal Fissure
    Medical condition: Anal Fissure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-010811-34 Sponsor Protocol Number: 113018 Start Date*: 2009-04-16
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase III, open, non-randomized, multi-centric, single dose study to assess mmunogenicity and safety of Fluarix / Influsplit SSW® 2009/2010 injected intramuscularly in young adults (18 to 60 year...
    Medical condition: Immunization against influenza of healthy adults.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004343-21 Sponsor Protocol Number: LAM100036 Start Date*: Information not available in EudraCT
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures
    Medical condition: Epilepsy - Primary genralised tonic clonic seizures
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004342-41 Sponsor Protocol Number: LAM100034 Start Date*: 2005-04-28
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects with Partial Seizures
    Medical condition: Epilepsy -partial seizures
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001310-24 Sponsor Protocol Number: 111631 Start Date*: 2008-05-30
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase III, open, non-randomized, multi-centric, single dose study to assess immunogenicity and safety of Fluarix™ / Influsplit SSW® 2008/2009 injected intramuscularly in young adults (18 to 60 ye...
    Medical condition: Immunization against influenza of healthy adults.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003248-31 Sponsor Protocol Number: 110806 Start Date*: 2007-11-16
    Sponsor Name:GSK Biologicals
    Full Title: An open, phase IV, non-randomised, single-centre study with two study groups to assess the immunogenicity and reactogenicity of a booster dose of GlaxoSmithKline (GSK) Biologicals' combined reduced...
    Medical condition: Booster vaccination against diphtheria, tetanus and pertussis diseases in adults
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2010-022384-35 Sponsor Protocol Number: CCX114644 Start Date*: 2011-02-02
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects with Crohn’s Disease
    Medical condition: Subjects with Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Prematurely Ended) SE (Prematurely Ended) GB (Prematurely Ended) CZ (Prematurely Ended) DK (Prematurely Ended) HU (Prematurely Ended) GR (Prematurely Ended) AT (Completed) PL (Prematurely Ended) ES (Prematurely Ended) PT (Prematurely Ended) EE (Completed) IT (Completed) SK (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-007876-41 Sponsor Protocol Number: 111567 Start Date*: 2008-03-07
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, randomized, open study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ Hepatitis B vaccine (Engerix-B™) when co-administered with GlaxoSmithKline Biologicals...
    Medical condition: Cervarix™ is indicated for the prevention of high-grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000913-35 Sponsor Protocol Number: BECRO/OV/DORZO Start Date*: 2019-05-21
    Sponsor Name:BECRO (Cyprus) Ltd
    Full Title: A Randomized, Observer-blind, two Parallel Group, Multi-center, Clinical Trial for Comparing the Efficacy and Tolerability of Dorzo-Vision® sine Preservative-Free Eye Drops vs. Trusopt® Preservativ...
    Medical condition: Open angle glaucoma or ocular hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10015919 Eye disorders SOC
    20.0 10015919 - Eye disorders 10030348 Open angle glaucoma PT
    20.0 10015919 - Eye disorders 10030043 Ocular hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001046-19 Sponsor Protocol Number: ORA-D-N01B Start Date*: 2020-08-13
    Sponsor Name:Oramed Ltd.
    Full Title: An Open-Label Multi-Center Study to Assess the Safety and Potential of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients with Nonalcoholic Steatohepatitis (NASH)
    Medical condition: Type 2 Diabetes Patients with Nonalcoholic Steatohepatitis (NASH)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001429-16 Sponsor Protocol Number: HORA-PDE6B-001 Start Date*: 2017-07-28
    Sponsor Name:HORAMA SA
    Full Title: Safety and Efficacy of a Unilateral Subretinal Administration of HORA-PDE6B in Patients Harboring Mutations in the PDE6B Gene Leading to a Defect in PDE6B Expression.
    Medical condition: Retinitis Pigmentosa
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000050-22 Sponsor Protocol Number: SEGCG18-01 Start Date*: 2018-04-24
    Sponsor Name:Skåne University Hospital, Department of Oncology
    Full Title: Irinotecan-based triplet (FOLFOXIRI) as perioperative treatment in resectable gastric and gastroesophageal junction adenocarcinoma.
    Medical condition: Resectabel gastric and gastroesophageal junction adenocarcinoma.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10056267 Gastroesophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 08 07:25:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA